Otium Capital: one of the leaders in private equity in France
Pierre-Edouard Sterin, founder of Smartbox gift boxes, created Otium Capital in 2009. This family office is responsible for supporting managers with the dual culture of entrepreneur and investor. The structure currently manages one billion euros in assets, with more than 70 holdings distributed between venture companies, growth companies, LBOs and various listed companies. Otium Capital, which owns 99% of Smartbox Group, will sell its shares to Wonderbox, allowing the two companies to open up new prospects by combining their strengths and expertise.
These sales will allow Otium Capital to strengthen its investments in key sectors: venture technology, in which the group is recognized as a leading player; the industrial enterprise, in which the first investments were made in 2022; local leisure, with the aim of opening 1,000 points of sale throughout the world in 10 years; growth, opportunistic LBOs and real estate, the last sector of intervention.
At the same time, Otium Capital continues to incubate business projects within its studio and supports Pierre-Edouard Stérin’s philanthropic ambitions through the common good fund.
Quantum genomics: an opportunity to seize
Although Otium Capital’s investments are by definition opportunistic, they meet strict criteria: the supported project must have a strong differentiating or innovative character; it must also be scalable and serve a deep market. Finally, you must have the support of a competent, complementary and committed team.
In recent months, the global market has suffered a strong discount, often uncorrelated with the performance of companies. The medtech and biotech sectors, despite their dynamism, have not been exempted, which represents a real boon for potential buyers. By questioning independent scientists or scientists involved in the studies, as well as competent financial analysts and observers in its network, Otium Capital has forged the conviction that Quantum Genomics perfectly meets its investment criteria and has very strong potential to create value. in the months and months. coming years, with expected results from Fresh and Refresh’s phase 3 trials of its solution for resistant high blood pressure. With this certainty, Otium Capital intends to support Quantum Genomics until commercial success.
This content was produced with AGENCE DELTA. The BFMBUSINESS editorial team was not involved in the production of this content.
Source: BFM TV
